{
    "2018-02-21": [
        [
            {
                "time": "2018-01-02",
                "original_text": "How An AbbVie Deal Sent This Biotech Stock To A 2-Year High",
                "features": {
                    "keywords": [
                        "AbbVie",
                        "Deal",
                        "Biotech",
                        "Stock",
                        "2-Year High"
                    ],
                    "sentiment_score": 0.9,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "biotech",
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2018-01-03",
                "original_text": "ANTH Awaits RESULT In Mar., HAIR Grows, NITE Shines, TRXC On Must-watch List",
                "features": {
                    "keywords": [
                        "ANTH",
                        "RESULT",
                        "HAIR",
                        "NITE",
                        "TRXC"
                    ],
                    "sentiment_score": 0.7,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "biotech"
                    ],
                    "causal_factor": "false",
                    "causal_impact": "neutral",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2018-01-04",
                "original_text": "Here’s What The AbbVie and Voyager Therapeutics Deal Really Means",
                "features": {
                    "keywords": [
                        "AbbVie",
                        "Voyager Therapeutics",
                        "Deal"
                    ],
                    "sentiment_score": 0.8,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "biotech",
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2018-01-05",
                "original_text": "Can Johnson & Johnson Replace Remicade for $100 Million Upfront?",
                "features": {
                    "keywords": [
                        "Johnson & Johnson",
                        "Remicade",
                        "Replace",
                        "$100 Million"
                    ],
                    "sentiment_score": 0.6,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2018-01-06",
                "original_text": "AbbVie, Neurocrine shares rise after positive results for uterine fibroids drug",
                "features": {
                    "keywords": [
                        "AbbVie",
                        "Neurocrine",
                        "positive results",
                        "uterine fibroids drug"
                    ],
                    "sentiment_score": 0.85,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2018-01-07",
                "original_text": "AbbVie Announces Positive Topline Results from Phase 3 Study Evaluating Investigational Elagolix in Women with Uterine Fibroids",
                "features": {
                    "keywords": [
                        "AbbVie",
                        "Positive Topline Results",
                        "Phase 3",
                        "Elagolix",
                        "Uterine Fibroids"
                    ],
                    "sentiment_score": 0.9,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2018-01-08",
                "original_text": "Canadians living with Moderate to Severe Hidradenitis Suppurativa are beginning to have public access to HUMIRA® (Adalimumab) to manage their disease",
                "features": {
                    "keywords": [
                        "Canadians",
                        "Hidradenitis Suppurativa",
                        "HUMIRA",
                        "Adalimumab"
                    ],
                    "sentiment_score": 0.75,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "healthcare",
                        "pharmaceuticals"
                    ],
                    "causal_factor": "false",
                    "causal_impact": "neutral",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "neutral"
                }
            },
            {
                "time": "2018-01-09",
                "original_text": "AbbVie Reports Positive Topline Results From Phase 3 Elagolix Study",
                "features": {
                    "keywords": [
                        "AbbVie",
                        "Positive Topline Results",
                        "Phase 3",
                        "Elagolix"
                    ],
                    "sentiment_score": 0.9,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2018-01-10",
                "original_text": "Trial Tests FTC’s Power to Referee Drug Makers’ Fight Against Generics",
                "features": {
                    "keywords": [
                        "Trial",
                        "FTC",
                        "Drug Makers",
                        "Generics"
                    ],
                    "sentiment_score": 0.5,
                    "policy_related": "true",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "pharmaceuticals",
                        "regulation"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "negative",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "negative"
                }
            }
        ]
    ]
}